利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

115 条记录 (耗时 0.037 秒)

    Stable Therapeutic Proteins
    51.
    发明申请
    Stable Therapeutic Proteins 审中-公开
    稳定的治疗蛋白

    公开(公告)号：US20110009324A1

    公开(公告)日：2011-01-13

    申请号：US12879821

    申请日：2010-09-10

    申请人： Johann Eibl

    发明人： Johann Eibl

    IPC分类号： A61K38/36 ,  A61K38/37 ,  A61P7/04 ,  C07K14/75 ,  C07K14/755

    CPC分类号： A61K38/37 ,  A61K38/36 ,  A61K38/363

    摘要： The invention relates to storable medicaments produced from pharmaceutical active ingredient preparations which are virus safe. Said medicaments contain at least one intact therapeutic protein obtained from plasma or by means of genetic engineering, as an active pharmaceutical substance. Said active ingredient preparations contain active enzymes, especially proteases, which are either free or bound to the substrates thereof and act against the therapeutic protein(s) present.

    摘要翻译： 本发明涉及由病毒安全的药用活性成分制剂制备的可储存药物。 所述药物含有至少一种从血浆或通过基因工程获得的完整治疗蛋白质作为活性药物。 所述活性成分制剂含有活性酶，特别是蛋白酶，它们与其底物游离或结合，并且对抗存在的治疗性蛋白质。

    Pharmaceutical preparations and medicines capable of generating, and/or containing, thrombin
    52.
    发明授权
    Pharmaceutical preparations and medicines capable of generating, and/or containing, thrombin 有权
    能够产生和/或含有凝血酶的药物制剂和药物

    公开(公告)号：US07494971B2

    公开(公告)日：2009-02-24

    申请号：US11041165

    申请日：2005-01-21

    申请人： Johann Eibl

    发明人： Johann Eibl

    IPC分类号： A61K38/36 ,  C07K14/00

    CPC分类号： A61K38/36 ,  A61K2300/00

    摘要： The invention relates to a pharmaceutical active ingredient preparation for producing a medicament that contains thrombin or has a thrombin-generating capacity and compositions comprising thereof. The inventive preparation contains: (A) prothrombin obtained from plasma or by means of genetic engineering (coagulation factor II), (B) coagulation factors V, VIII, IX, X obtained from plasma or by means of genetic engineering, which can be at least partially in the activated state, and coagulation factor Xla obtained from plasma or by means of genetic engineering, and (C) phospholipids which are safe from prions and contribute to the clotting process, said phospholipids being optionally contained in liposomes.

    摘要翻译： 本发明涉及一种用于生产含有凝血酶或具有凝血酶生成能力的药物的药物活性成分制剂及其组合物。 本发明的制剂包含：（A）从血浆或通过基因工程（凝血因子II）获得的凝血酶原，（B）从血浆或通过遗传工程获得的凝血因子V，VIII，IX，X，其可以在 至少部分为活化状态，以及由血浆或通过遗传工程获得的凝血因子Xla，和（C）磷酸蛋白，其从朊病毒中是安全的并且有助于凝血过程，所述磷脂任选地包含在脂质体中。

    Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
    60.
    发明授权
    Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen 失效
    使用lys-plasminogen预防和治疗由此导致的缺血事件和再灌注损伤

    公开(公告)号：US5520912A

    公开(公告)日：1996-05-28

    申请号：US257626

    申请日：1994-06-08

    申请人： Johann Eibl ,  Ludwig Pichler ,  Hans-Peter Schwarz

    发明人： Johann Eibl ,  Ludwig Pichler ,  Hans-Peter Schwarz

    IPC分类号： A61K38/00 ,  A61K38/43 ,  A61K38/46 ,  A61K38/48 ,  A61P9/00 ,  A61P9/10 ,  A01N37/18

    CPC分类号： A61K38/484 ,  Y10S514/802

    摘要： A treatment of ischemia and the attendant reperfusion injury entails the administration plasmin and plasmin-forming proteins, including lys-plasminogen and similar substances. Lys-plasminogen, which can be obtained from the proteolytic cleavage of glu-plasminogen, has been found to have a protective effect on tissue that has been injured by ischemic conditions. The administration of lys-plasminogen can used to treat subjects during the time of reperfusion and after reperfusion has already occurred. Lys-plasminogen also can be administered in conjunction with clot lysis therapies, such as those that employ tissue plasminogen activator and the like.

    摘要翻译： 缺血和伴随的再灌注损伤的治疗需要施用纤溶酶和纤溶酶形成蛋白，包括溶酶原纤溶酶原和类似物质。 已经发现，可以从葡萄糖分解纤维蛋白溶酶原的蛋白水解切割中获得的Lys-plasminogen对缺血条件损伤的组织具有保护作用。 溶血纤溶酶原的施用可以在再灌注期间和再灌注已经发生后用于治疗受试者。 Lys-纤溶酶原也可以与凝块溶解疗法结合使用，例如使用组织纤溶酶原激活剂等的那些。